Sangamo Therapeutics Inc (NASDAQ:SGMO) Director Steven J. Mento sold 11,520 shares of Sangamo Therapeutics stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $20.59, for a total value of $237,196.80. Following the transaction, the director now directly owns 5,000 shares in the company, valued at approximately $102,950. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Sangamo Therapeutics Inc (NASDAQ:SGMO) traded down $0.85 on Monday, reaching $18.80. The company’s stock had a trading volume of 2,210,000 shares, compared to its average volume of 1,320,000. The firm has a market capitalization of $1,590.00, a price-to-earnings ratio of -27.25 and a beta of 2.87. Sangamo Therapeutics Inc has a 52 week low of $3.55 and a 52 week high of $21.90. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.64 and a current ratio of 5.64.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.04. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The company had revenue of $11.81 million for the quarter, compared to the consensus estimate of $10.37 million. During the same period last year, the business posted ($0.27) EPS. The company’s revenue was up 333.0% on a year-over-year basis. sell-side analysts predict that Sangamo Therapeutics Inc will post -0.73 earnings per share for the current fiscal year.
SGMO has been the topic of several research analyst reports. Zacks Investment Research lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, January 5th. Jefferies Group reaffirmed a “buy” rating and set a $18.00 price target on shares of Sangamo Therapeutics in a research report on Friday, October 13th. Piper Jaffray Companies raised Sangamo Therapeutics from a “neutral” rating to an “overweight” rating and set a $19.00 price target on the stock in a research report on Wednesday, November 15th. BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, January 24th. Finally, Wedbush reaffirmed a “hold” rating and set a $6.00 price target on shares of Sangamo Therapeutics in a research report on Wednesday, November 15th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $18.83.
TRADEMARK VIOLATION NOTICE: “Steven J. Mento Sells 11,520 Shares of Sangamo Therapeutics Inc (SGMO) Stock” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.americanbankingnews.com/2018/02/05/steven-j-mento-sells-11520-shares-of-sangamo-therapeutics-inc-sgmo-stock.html.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.